First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

Janux Therapeutics has a robust balance sheet, with $658.1 million in liquid assets and no debt. See why I reiterate my buy ...

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

Investing.com -- Shares of Vir Biotechnology, Inc. (NASDAQ: VIR) surged 29% following the release of encouraging safety and efficacy data from ongoing dose escalation trials for its dual-masked T-cell ...

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma.

The FDA granted priority review to sunvozertinib for the treatment of advanced NSCLC with EGFR exon 20 mutations, based on ...

Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...